Thursday, 25 February 2016

Analysis,Competitive landscape & Depth Report of Type 2 Diabetes Mellitus Therapeutics Market 2021

Type 2 Diabetes mellitus (T2DM) is a disease marked by lack of insulin, insulin resistance, and high blood sugar. This disease has long-term damage that results in failure and dysfunction of multiple organs including blood vessels, heart, nerves, kidneys, and eyes. About 85% of diabetics have the chances of getting T2DM. The rising cases of diabetes can be attributed to reduced physical activity and consumption of high-calorie diets. A healthy diet and lifestyle change can improve the chances of recovering from T2DM.

The T2DM therapeutics market in Asia Pacific has evolved in the last decade. It has brought about promising treatments such as SGLT-2 inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor, sulfonylureas, biguanide, and other insulin therapies. But alternative products offering better glycemic control hamper market growth. GIP (Gastric inhibitory polypeptide) is impaired during type 2 diabetes, but GLP-1 is preserved proving beneficial to therapy. 

For Further Inquiries:

Sulfonylureas help your body secrete more insulin. Examples of medication in this class of medicines are glipizide and glyburide. Meglitinides work similarly to sulfonylureas but are faster-acting agents. Examples of medication include nateglinide and repaglinide. DPP-4 inhibitors reduce blood sugar levels and negate the possibility of weight gain. Examples include saxagliptin and sitagliptin.

GLP-1 receptor agonists lower blood sugar level and slow digestion. Examples of this medication are liraglutide and exenatide. SGLT-2 inhibitors are newest drugs in the market which prevents sugar to be absorbed into the blood and excretes it through the urine.

Bariatric surgery is an option for obese patients suffering from T2DM. The T2DM therapeutics market in Asia Pacific is projected to reach about 10.2 billion by 2021, growing at a 7.7% CAGR from 2014 to 2021. It was previously estimated to be worth USD 6 billion in 2013. With over 500 active drugs in the pipeline, many drug-testing candidates are evaluated and given advanced drugs and insulin therapies. In an analysis of clinical trials, T2DM molecules had a failure rate of over 50% in Phase II, with an attrition rate of 86%.

Browse All Reports of This Category @

The T2DM therapeutics market covers the areas of China, India, Australia, and Japan in Asia Pacific. Notable players of the T2DM therapeutics market are AbbVie, Intarcia Therapeutics, Emisphere, Janssen, and Halozyme Therapeutics.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: Radiant Insights 

No comments:

Post a Comment